Source: Financial Modeling Prep · peers by sector/industry
Valuation
Trading at 0.0× sales vs its 0.5× historical median P/S.
Fair value ≈ $0.12 · price $0.01 today
Undervalued · 92% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$EMMA Q1 results show the double-edged sword of cost-cutting: Revenue dipped to $2.4M (-4% YoY) as generics bite, but operating loss narrowed to $1M. Cash reserves now at $1.3M - runway getting tight. The math remains brutal: sickle cell specialization vs generic tsunami and negative equity. Survival mode continues.
https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302457162.html
$EMMA - Emmaus Life Sciences, Inc. - 10K - Updated Risk Factors
EMMA faces intensified risks in 2025: widened $9.3M loss, liquidity crunch with debt due and no refinancing, Endari’s U.S. exclusivity expired amid new generic competition and pricing pressure, regulatory setbacks, supply chain issues, and increased dilution and trading volatility risks. #Pharmaceuticals #MarketCompetition #SupplyChain #RegulatoryRisk #FinancialRisk
🟢 Added 🟠 Removed
https://d-risk.ai/EMMA/10-K/2025-04-14
$EMMA's 2024 results paint a grim picture: revenues plummeted 44% due to inventory mismanagement, now sitting on just $1.4M cash. While cost-cutting helped slightly, the $0.10/share loss and negative ops income reveal structural issues. CEO's 2025 optimism feels like rearranging deck chairs on the Titanic - especially with gene therapies looming.
https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-2024-financial-results-302428165.html
$QSI - Should I keep QuantumSi and Emmaus Life ( $EMMA ) in the same portfolio? Next fiscal quarter end is on 30th of September 2023 https://www.macroaxis.com/invest/pair-correlation/QSI/EMMA/QuantumSi-vs-Emmaus #portfolio_prospective #better_portfolio #diversify
